Following oral arguments before the U.S. Supreme Court in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., Chad Landmon was featured in legal, intellectual property and life sciences publications discussing the questions before the Court and the potential implications of the forthcoming decision. His commentary focused on the future of skinny labeling, the standards for induced infringement and the potential impact the case could have on pharmaceutical innovation and generic drug competition.

See media coverage below.

Justices to side with generic drugmakers in patent spat, attorneys predict
Westlaw Today

SCOTUS judges favour fact-specific approach to landmark ‘skinny label’ dispute
IAM

Hot Takes: What the Oral Arguments in Hikma/ Amarin Revealed
IP Watchdog

Supreme Court Decision Hangs In Balance After Hikma-Amarin Skinny-Label Oral Arguments
Citeline

High Court Seeks Path To Limited Ruling On 'Skinny Labels'
Law360

Supremes weigh in on skinny labels in long-awaited argument
BioWorld

Supreme Court justices appear to signal 'skinny labeling' can survive
STAT News